688553 汇宇制药
2025/06 - 中期
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额(27,066)242,95666,933194,060446,363
投资活动产生之现金流量净额(18,999)270,457233,348(181,034)(1,872,122)
筹资活动产生之现金流量净额(89,726)(86,299)122,298(99,990)2,347,248
汇率变动对现金及现金等价物的影响3,960671,641(161)(42)
现金及现金等价物净增加/(减少)(131,830)427,180424,219(87,125)921,447
期初现金及现金等价物余额2,057,2441,630,0641,205,8451,292,970371,522
期末现金及现金等价物余额1,925,4142,057,2441,630,0641,205,8451,292,970